Abbott, AstraZeneca to co-promote Certriad

ABBOTT PARK, Ill. The same day they agreed to co-promote a cholesterol-lowering drug, Abbott Labs and AstraZeneca have submitted a regulatory approval application for a new drug to treat another lipid disorder.

The two companies announced Thursday that they had submitted the application for Certriad, which treats mixed dyslipidemia, a combination of high “bad” LDL cholesterol, high triglycerides and low “good” HDL cholesterol.

“Patients with mixed dyslipidemia are an underserved segment of the dyslipidemic population,” Abbott VP global pharmaceutical clinical development Eugene Sun said in a statement. “If approved, Certriad could become an important treatment option for physicians looking to provide comprehensive management of mixed dyslipidemia to their patients.”